Krystal Biotech Reports the First Patient Dosing of KB407 in P-I Clinical Trial for the Treatment of Cystic Fibrosis
Shots:
- The 1st patient has been dosed in the P-I trial of KB407 at the Cystic Fibrosis Institute of Chicago. 3 cohorts will be incl. in the study with the 1st two cohorts each containing 5 patients while 10 in the last cohort
- The study continues to enrol patients & the results are expected in 2024. The 1EPs will be the safety & tolerability of nebulized KB407. Percent projected forced expiratory volume in one second (ppFEV1) will measure changes in lung function from baseline, vector shedding & biodistribution will assess in blood, urine, buccal & sputum samples
- The study incl. a bronchoscopy sub-study to evaluate the nucleic acid & protein levels of CFTR transgenic expression in the airways. At select sites, patients undergo an optional bronchoscopy 24-96hrs. after the last dose of KB407
Ref: Globenewswire | Image: Krystal Biotech
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
